I don't think there will be a reverse split any time soon. As stated in the February letter to shareholders regarding the Antisenilin patent:
"...which will trigger the milestone payments and greatly increase the royalties payable to Intellect when drugs based on its technology reach the market. We expect a decision from the USPTO on our ANTISENILIN(R) patent application within the next several months."
Look what happened last week when news was released about the other patent which, unlike the Antisenilin patent, did not trigger milestone payments. What will be the market reaction to 7 figures entering the company treasury?
Furthermore, regarding OX1 Phase I testing by i3,
"...We expect to receive data and a report from i3 during the next quarter.
So it appears there will be MARKET MOVING information released over the next few months. The company will wait until the price rises before issuing more stock, hence no RV.
